Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
JUNEL FE 1.5/30 vs ALYACEN 7/7/7
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination estrogen-progestin contraceptive; suppresses gonadotropin release (FSH, LH) via negative feedback, inhibiting ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.
Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.
Prevention of pregnancy,Treatment of moderate acne vulgaris (in females ≥15 years who desire contraception and have not responded to topical therapy)
Prevention of pregnancy
One tablet orally once daily, each tablet containing norethindrone acetate 1.5 mg and ethinyl estradiol 30 mcg, taken at the same time each day for 21 days followed by 7 days of placebo (iron tablets).
ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.
Norethindrone: 6-12 hours (terminal, multidose); ethinyl estradiol: 12-18 hours (terminal). Clinical context: Steady-state achieved within 5-7 days; missed doses may reduce contraceptive efficacy.
Terminal elimination half-life is 14 hours (range 12-16 h) in healthy adults; prolonged to 24-30 h in moderate renal impairment (Cr Cl 30-50 m L/min).
Ethinyl estradiol: primarily metabolized via CYP3A4; norethindrone: primarily reduced and conjugated, with CYP3A4 involvement.
Norethindrone: primarily hepatic via reduction and conjugation, with CYP3A4 involvement. Ethinyl estradiol: primarily via CYP3A4, also undergoes sulfation and glucuronidation.
Renal: 30-50% (norethindrone metabolites), 20-40% (ethinyl estradiol metabolites); biliary/fecal: 20-30% (norethindrone), 30-50% (ethinyl estradiol). Conjugated metabolites excreted in bile and undergo enterohepatic recirculation.
Renal: ~50% (unchanged drug); Fecal: ~20% (via bile); Biliary: ~30% (metabolites). Total clearance is 12 L/h.
Norethindrone: 60-80% bound to albumin and SHBG; ethinyl estradiol: ~98% bound to albumin (specific binding to SHBG not significant).
98% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein.
Norethindrone: 2-4 L/kg; ethinyl estradiol: 5-10 L/kg. Clinical meaning: Indicates extensive tissue distribution and slow clearance; Vd may increase in obesity.
0.35 L/kg (total body water distribution); in obesity, Vd increases to 0.5 L/kg due to lipophilicity.
Oral: Norethindrone ~60-70% (first-pass metabolism); ethinyl estradiol ~40-50% (presystemic conjugation in gut and liver).
Oral: 85% (with high-fat meal reduces to 70%); Sublingual: 90%.
No specific dose adjustment provided in labeling; use with caution in patients with renal impairment. GFR-based modifications not established.
Contraindicated in patients with severe renal impairment (Cr Cl <30 m L/min) or acute renal failure due to drospirenone's antimineralocorticoid activity. No dose adjustment recommended for mild to moderate impairment (Cr Cl ≥30 m L/min).
Contraindicated in patients with hepatic impairment (Child-Pugh class B or C) or active liver disease. No specific dose adjustment for mild impairment; use with caution.
Contraindicated in patients with acute hepatic disease, hepatic tumors, or impaired liver function (Child-Pugh class B or C). Discontinue if jaundice or pruritus develops. No dose adjustment for Child-Pugh class A.
Not indicated for use before menarche. In post-menarche adolescents, dosing is the same as adults: one tablet daily for 21 days, then 7 days placebo.
Not indicated for use in pediatric patients before menarche. Safety and efficacy in postmenarchal adolescents are expected to be similar to adults; dose is same as adults.
Not indicated for use in postmenopausal women; no specific geriatric dosing considerations.
Not indicated for use in postmenopausal women. No recommendations for geriatric population due to lack of indication.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women >35 years) and with number of cigarettes smoked. Women >35 years who smoke should not use this product.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives (COCs). Risk increases with age and amount smoked (especially >15 cigarettes/day). Women over 35 who smoke should not use COCs.
Increased risk of thromboembolic disorders (e.g., DVT, PE, stroke, MI),Hepatic neoplasia risk,Liver disease (e.g., jaundice, hepatitis),Elevated blood pressure,Gallbladder disease,Carbohydrate/lipid metabolic effects,Ocular lesions (e.g., retinal thrombosis),Menstrual irregularities/breakthrough bleeding,Use in pregnancy (should be ruled out before initiation),Depression
Thrombotic disorders (thrombophlebitis, pulmonary embolism, cerebral hemorrhage, myocardial infarction),Cerebrovascular disease,Carcinoma of the breast or reproductive organs,Hepatic adenoma or carcinoma,Ocular lesions (retinal thrombosis, papilledema),Gallbladder disease,Carbohydrate/lipid effects,Elevated blood pressure,Hereditary angioedema,Chloasma,Hepatic impairment
Hypersensitivity to any component,Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease,Known or suspected pregnancy,Undiagnosed abnormal genital bleeding,Known or suspected breast cancer or other estrogen-sensitive neoplasia,Benign or malignant liver tumor (current or history),Hepatic adenoma or carcinomas,Active liver disease with abnormal function tests,Major surgery with prolonged immobilization,Diabetes with vascular involvement,Uncontrolled hypertension,Migraine with focal neurological symptoms (current or history),Smoking in women >35 years
Breast cancer (current or history),Undiagnosed abnormal genital bleeding,Known or suspected pregnancy,Current or history of thrombotic disorders (DVT, PE, stroke, MI),Cerebrovascular or coronary artery disease,Valvular heart disease with complications,Severe hypertension,Diabetes with vascular disease,Headaches with focal neurological symptoms (e.g., migraine with aura),Major surgery with prolonged immobilization,Known thrombophilia (e.g., Factor V Leiden, prothrombin mutation, protein S/C deficiency),Active liver disease (tumors, hepatitis, cirrhosis),Uncontrolled hypertension,Smoking (if age >35),Hypersensitivity to any component
No specific food interactions are reported. However, grapefruit juice may increase ethinyl estradiol levels but interaction is considered weak; avoid excessive grapefruit juice consumption. Ferrous fumarate may reduce absorption of tetracycline antibiotics if taken together; space doses by at least 2 hours. No dietary restrictions are required.
Grapefruit and grapefruit juice may increase ethinyl estradiol levels, potentially increasing side effects. St. John's wort (herbal supplement) can reduce contraceptive efficacy. No other significant food interactions; however, maintaining a stable intake of vitamin C and folate is generally recommended.
First trimester: Inadvertent use does not increase risk of major birth defects. Second and third trimesters: Avoid use due to risk of fetal harm from estrogenic and progestogenic effects, including potential genitourinary tract abnormalities. Postnatal effects: Possible long-term neurodevelopmental impacts reported in animal studies.
ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does not warrant termination. Second and third trimesters: Avoid use due to potential adverse effects on fetal development, including feminization of male fetuses and potential for congenital anomalies from progestin. Postnatal: Possible long-term effects on reproductive development.
Excreted in breast milk in small amounts; M/P ratio for ethinyl estradiol approximately 0.04–0.30. Progestin M/P ratio variable. May reduce milk production and quality. Use only if necessary and with caution, especially in early postpartum period.
Contraindicated in breastfeeding. Ethinylestradiol reduces milk quantity and quality. Norethindrone is excreted in low amounts (M/P ratio approximately 0.3-0.4). However, combination oral contraceptives are not recommended during lactation due to estrogen effects on milk production.
Contraindicated during pregnancy; no dose adjustment exists. Discontinue immediately if pregnancy occurs. Pharmacokinetic changes in pregnancy (increased clearance, volume of distribution) are not applicable as drug is not used.
ALYACEN 7/7/7 is contraindicated in pregnancy; no dose adjustments are applicable as use is not recommended. Pharmacokinetic changes in pregnancy (increased clearance of steroids) would theoretically require higher doses, but due to fetal risks, alternative therapies should be used.
Junel Fe 1.5/30 is a combination oral contraceptive containing ethinyl estradiol 30 mcg and norethindrone 1.5 mg, with ferrous fumarate as placebo. Consider starting on first day of menses or first Sunday after onset. Missed pills increase pregnancy risk; if missing one pill, take as soon as remembered. For missed two pills in week 1 or 2, take two pills daily for two days and use backup contraception. If missed in week 3, consider finishing current pack and skipping placebo, or starting new pack the next day. Drug interactions include rifampin, certain anticonvulsants, and St. John's wort, which may reduce efficacy. Monitor for DVT, PE, stroke, and MI, especially in smokers over 35, hypertensive, diabetic, or obese patients.
ALYACEN 7/7/7 is a triphasic oral contraceptive containing ethinyl estradiol and norgestimate. The 7/7/7 regimen refers to the varying doses of norgestimate across three 7-day phases (0.18 mg, 0.215 mg, 0.25 mg) with a fixed 0.025 mg ethinyl estradiol. Use consistent 7-day placebo interval. Consider increased risk of venous thromboembolism (VTE) in patients with BMI >30, smoking >15 cigarettes/day, or age >35. Monitor for breakthrough bleeding, especially during the first 3 cycles. Avoid in patients with migraine with aura, uncontrolled hypertension, or history of DVT/PE. Drug interactions with CYP3A4 inducers (e.g., rifampin, carbamazepine) may reduce efficacy; consider backup contraception.
Take one tablet daily at the same time; do not skip days.,If you miss a pill, refer to the package instructions or ask your healthcare provider.,Use backup contraception (e.g., condoms) if you miss pills or start late.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Seek emergency care for severe abdominal pain, chest pain, leg swelling, or vision changes.,Smoking increases risk of serious cardiovascular effects; avoid smoking, especially if over 35.,Iron supplements are included; ferrous fumarate in placebo tablets is not effective for contraception.
Take one pill daily at the same time each day, in the order specified on the pack (active pills followed by placebo).,If you miss a pill, follow the package instructions; missing pills increases pregnancy risk, especially if placebo week is extended.,Common side effects include nausea, headache, breast tenderness, and spotting, which usually improve after 2-3 cycles.,Seek immediate medical attention for severe abdominal pain, chest pain, shortness of breath, leg pain/swelling, or severe headache.,This medication does not protect against HIV/AIDS or other sexually transmitted infections (STIs).,Inform your healthcare provider if you smoke, as smoking increases risk of serious cardiovascular side effects, especially if over 35 years.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about JUNEL FE 1.5/30 vs ALYACEN 7/7/7, answered by our medical review team.
JUNEL FE 1.5/30 is a Oral Contraceptive that works by Combination estrogen-progestin contraceptive; suppresses gonadotropin release (FSH, LH) via negative feedback, inhibiting ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.. ALYACEN 7/7/7 is a Oral Contraceptive that works by Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between JUNEL FE 1.5/30 and ALYACEN 7/7/7 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of JUNEL FE 1.5/30 is: One tablet orally once daily, each tablet containing norethindrone acetate 1.5 mg and ethinyl estradiol 30 mcg, taken at the same time each day for 21 days followed by 7 days of placebo (iron tablets).. The standard adult dose of ALYACEN 7/7/7 is: ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between JUNEL FE 1.5/30 and ALYACEN 7/7/7 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. JUNEL FE 1.5/30 is classified as Category C. First trimester: Inadvertent use does not increase risk of major birth defects. Second and third trimesters: Avoid use due to risk of fetal harm from estrogenic and progestogenic e. ALYACEN 7/7/7 is classified as Category C. ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does n. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.